Retinal Nerve Fiber Layer Thickness Using Spectral-Domain Optical Coherence Tomography in Patients With No Light Perception Secondary to Optic Atrophy

Download item | Update item information
Title Retinal Nerve Fiber Layer Thickness Using Spectral-Domain Optical Coherence Tomography in Patients With No Light Perception Secondary to Optic Atrophy
Creator Groth, Sylvia L; Harrison, Andrew; Grajewski, Alana L; Lee, Michael S
Affiliation Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota
Subject Adult; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Light; Male; Middle Aged; Nerve Fibers; Optic Atrophy; Retinal Neurons; Retrospective Studies; Tomography, Optical Coherence; Visual Acuity
Abstract Optical coherence tomography (OCT) provides useful structural information that can augment functional data. Newer spectral-domain technology provides faster and higher resolution images than time-domain machines. Although each measures the same structures, the values systematically differ. We evaluated eyes with longstanding no light perception (NLP) visual acuity secondary to optic atrophy using spectral-domain OCT to determine minimum retinal nerve fiber layer (RNFL) thickness. The authors conducted a retrospective, crosssectional chart review study to identify patients with NLP acuity for 8 months or more and having a good quality Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany) to measure the RNFL thickness. An unpaired t test compared the eyes with a previously published data set measured with time-domain OCT. Eleven eyes from 10 patients were examined with the Spectralis OCT. The mean duration of documented NLP acuity was 3.72-1.20 years. The mean RNFL thickness was 34.18 - 2.66 mm (95% coincidence interval, 28.26 40.11 mm). Mean RNFL thickness was significantly thinner on this spectral-domain OCT than previously published values on time-domain OCT (34.18 vs 45.42 mm, P = 0.004). Using the Spectralis OCT, mean RNFL thickness for NLP eyes due to optic atrophy is 28-40 mm. This provides clinicians useful information when considering how aggressively to manage patients with optic nerve disease.
OCR Text Show
Date 2013-03
Type Text
Rights Management © North American Neuro-Ophthalmology Society
Publication Type Journal Article
ARK ark:/87278/s6rf915w
Setname ehsl_novel_jno
Date Created 2014-03-24
Date Modified 2014-07-10
ID 227376
Reference URL https://collections.lib.utah.edu/ark:/87278/s6rf915w